Pharmafile Logo
Pharmafocus logo
Advanced Search

Vaccitech’s VTP-200 Ph 1b/2 Study Demonstrates Favorable Tolerability and Immunogenicity Profile at Interim Analysis in Women with Low-Grade Human Papillomavirus (HPV)-related Cervical Lesions

March 21, 2023
Business Services

OXFORD, United Kingdom, March 20, 2023 (GLOBE NEWSWIRE) — Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company focused on the …

News
Press release

BioNTech and OncoC4 to partner for development and commercialisation of novel checkpoint antibody

March 21, 2023
Sales and Marketing

BioNTech and OncoC4 have entered a strategic collaboration for the co-development and commercialisation of a novel checkpoint antibody for multiple …

News

First candidate from Nurix-Gilead Sciences collaboration exclusively licensed

March 21, 2023
Research and Development

US-based Gilead Sciences and Nurix have announced that Gilead has exercised its option to exclusively license Nurix’s investigational targeted protein …

News

FDA staff appear to support Biogen’s ALS drug despite limited data

March 21, 2023
Medical Communications

It appears that the FDA is inclined to support Biogen’s amyotrophic lateral sclerosis (ALS) drug, tofersen, with documents released on …

News

FDA approves Surgvision’s Explorer Air II device

March 21, 2023
Medical Communications

Medical technology company Surgvision has announced that it has received FDA 510(k) approval for its Explorer Air II device. It …

News

Mobiquity Report Reveals Top Mobile Health App Features that help to increase patient engagement.

March 20, 2023
Business Services

Mobiquity, a digital consultancy that designs and delivers innovative digital products and services for the world’s leading brands, released today …

News
Press release

AbbVie shares results from study for new psoriasis therapy

March 20, 2023
Research and Development

AbbVie has announced new 52-week data from a study assessing the efficacy of new IL-23 inhibitor, Skyrizi (risankizumab). Patients with …

News

QurAlis Corporation announces programme which targets UNC13A mis-splicing in neurodegenerative diseases

March 20, 2023
Research and Development

US-based clinical-stage biotechnology QurAlis Corporation has announced the launch of its newest programme to treat neurodegenerative diseases like ALS and …

News

AstraZeneca and MSD announce MHRA marketing authorisation of Lynparza combination therapy

March 20, 2023
Medical Communications

AstraZeneca and MSD have announced that the MHRA has granted marketing authorisation for Lynparza (olaparib) in the UK, when used …

News

Oxford Nanopore and 4bases collaborate on kit for BRCA1 and BRCA2 gene analysis

March 20, 2023
Medical Communications

Oxford Nanopore Technologies and Swiss company 4bases have announced a collaboration making 4bases kits with Oxford Nanopore’s sequencing technology. These …

News

NICE recommends OXLUMO®▼ (lumasiran) in England as first therapy to treat underlying cause of ultra-rare condition primary hyperoxaluria type 1 (PH1)

March 20, 2023
Business Services

MAIDENHEAD, UK, Monday 20th March 2023 – Alnylam UK Limited, the leading RNA interference (RNAi) therapeutics company, today welcomed a …

News
Press release

New data suggests investigational oral osteoarthritis drug APPA may have a promising senotherapeutic effect with potential in other diseases of ageing

March 20, 2023
Business Services

STEVENAGE, UK, March 20, 2023 – New data* presented at the 2023 Osteoarthritis Research Society International (OARSI) World Congress in …

News
Press release

Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset

March 20, 2023
Business Services

Basel, March 20, 2023 — Novartis today presented new data which underscore the transformational and sustained benefit of Zolgensma® (onasemnogene abeparvovec), …

News
Press release

Newron reports compelling topline results from all patients in Study 014, its Phase II clinical trial evaluating evenamide as add-on therapy for treatment-resistant schizophrenia

March 20, 2023
Business Services

Milan, Italy, March 20, 2023, 07:00 am CET – Newron Pharmaceuticals S.p.A.

News
Press release

Sun Pharma settles at $75m in industry-wide price-fixing case

March 17, 2023
Sales and Marketing

Sun Pharma has decided a settlement of $75m as part of a case surrounding various pharma companies fixing their prices. …

News

Sanofi to cut insulin prices by 78% starting January 2024

March 17, 2023
Sales and Marketing

French pharmaceutical company Sanofi has announced that it will cut the list price of its Lantus (insulin glargine injection) 100 …

News

FDA approves Novartis’ Tafinlar and Mekinist combination

March 17, 2023
Medical Communications

The FDA has approved Novartis’ combination therapy, Tafinlar (dabrafenib) and Mekinist (trametinib) for the treatment of BRAF V600E low-grade glioma …

News

CANbridge Pharmaceuticals reports positive long-term data for glioblastoma multiforme drug

March 17, 2023
Medical Communications

Chinese biopharmaceutical company CANbridge Pharmaceuticals has announced positive long-term follow-up data from its clinical studies into a glioblastoma multiforme (GBM) …

News

Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Nonmetastatic Prostate Cancer

March 17, 2023
Business Services

Addlestone UK, 17 March, 2023 –Astellas Pharma Ltd. (“Astellas”) today announced positive topline results from the Phase 3 EMBARK trial …

News
Press release

Newron to present at the 31st European Congress of Psychiatry

March 17, 2023
Business Services

Milan, Italy, March 17, 2023, 7am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused …

News
Press release
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025